SCHEMBL889015

SCHEMBL889015

CC(C)(C)OC(=O)N1CCCC1c1nc(-c2ccc3cc(Br)ccc3c2)c[nH]1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 6/20 0.43
KMT2A Q03164 2/20 0.41
UCHL1 P09936 4/20 0.41
ALDH1A1 P00352 1/20 0.39
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CHEK2 O96017 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12567354 0.97 USP30 (0.40) USP30KMT2AUCHL1ALDH1A1HCRTR1
SCHEMBL14924575 0.94 ALDH1A1 (0.43) USP30KMT2AUCHL1ALDH1A1L3MBTL1
SCHEMBL12104032 0.94 ALDH1A1 (0.43) USP30KMT2AUCHL1ALDH1A1L3MBTL1
SCHEMBL607195 0.92 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1
SCHEMBL607196 0.92 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1
SCHEMBL14841147 0.91 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1
Bromide SCHEMBL542121 0.91 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1
Bromide SCHEMBL542120 0.91 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1
SCHEMBL14924576 0.91 ALDH1A1 (0.41) USP30KMT2AUCHL1ALDH1A1L3MBTL1
SCHEMBL12333142 0.91 KMT2A (0.45) USP30KMT2AUCHL1ALDH1A1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064697-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, EIF2AK2, SLC10A1 USP30 2645/4885KMT2A 2992/4885UCHL1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.